Table 3.

Absorbed dose recommendations for ⁹⁰Y resin microspheres and the respective level of evidence (LOE)

	Single compartment		Multi-compartment
Clinical scenario	Perfused volume dose	LOE	Normal perfused liver dose	Tumour dose	LOE
HCC
Segmentectomy	> 150 [93]	4	Not applicable
Lobectomy	Not recommended		> 70 [93]*	≥ 100–120 [93]	4
Unilobar			< 40 [93]	≥ 100–120 [65]	3 4
Bilobar			< 30**/40 [93]	≥ 100–120 [65]	3 4
ICC
Segmentectomy	> 150 [93]	4	Not applicable
Lobectomy	Not recommended		> 70 [93]	≥ 100–120 [94]	3 4
Unilobar			< 40 [93]	≥ 100–120 *** [94]	3 4
Bilobar			< 30**/40 [93]	≥ 100–120 *** [94]	3 4
mCRC
Segmentectomy	> 150 [93]	4	Not applicable
Lobectomy	Not recommended		> 70 [93]	> 100 **** [93]	4
Unilobar			< 40 [93]	> 100 **** [95]	3 4
Bilobar			< 30**/40 [93]	> 100 **** [95]	3 4

Modified from Levillain et al. [93]

*Dose to the normal perfused liver with a hepatic reserve of >30%

**In pretreated patients or those with compromised liver function

***Longer OS for patients treated with a partition model-derived mean tumour dose of 86 Gy vs. BSA-derived tumour dose of 38 Gy

****Tumour absorbed doses >100 Gy have been associated with higher rates of metabolic complete response, whereas a lower threshold of >40–60 Gy predicted metabolic partial response